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Abstract:  The  frequency  of  coronary  heart  disease  (CHD)  is  increasing  among  HIV  seropositive 
persons. This phenomenon may be related to HIV disease itself, the use of antiretroviral medications 
and increased length of survival, or the synergism of these factors. In this study we have calculated the 
10-year  CHD  risk  estimate  and  the  prevalence  of  metabolic  syndrome  in  a  cohort  of  118  HIV 
seropositive  chronic  drug  users,  including  those  who  are  on  HAART  with  or  without  protease 
inhibitors  (PI).  The  results  showed  that  the  10-year  coronary  heart  disease  risk  among  the  HIV 
seropositive drug users was 4.8 ± 5.7, which is within the range of results published for other HIV 
infected cohorts. The 10-year CHD risk was significantly higher in men (5.9±6.1, p<0.001) than in 
women (1.7±2.4), due to their gender and the pre-menopausal mean age of the women (39.4±7.3 years 
of age), despite a significantly higher rate of abdominal obesity (54.8% in women vs. 8.1% in men, 
p<0.001)  and  lower  HDL  (61.3%  in  women  vs.  40%  in  men,  p=0.042).  The  rate  of  metabolic 
syndrome among our female HIV seropositive drug users was significantly higher (29% vs 10.3%, 
p=0.013) compared to men (10.3%). Participants with metabolic syndrome had a significantly higher 
10-year CHD risk (27.8% vs. 10.2%, p=0.041) and higher mean BMI (28.6 ± 4.1 vs. 24.2±4, p<0.001) 
than those without the syndrome. The predominant proportion of the cohort had a high viral load, 
suggesting  that  their  use  of  illicit  drugs  has  an  influence  on  either  adherence  or  effectiveness  of 
antiretroviral medication. Increased viral load was significantly associated with metabolic syndrome 
(OR=2.23, 95% CI:1.12, 4.47; p=0.023), high fasting glucose (OR=1.61, 95% CI: 1.02, 2.55; p=0.042) 
and  low  HDL  levels  (OR=1.41,  95%CI:  1.01,  1.98;  p=0.046),  after  controlling  for  age  gender, 
smoking, PI exposure, BMI and CD4. HAART with or without PI did not significantly impact the 10-
year CHD risk estimate or metabolic syndrome in this cohort. The estimated effect of PI, however, was 
positively and significantly related to triglyceride levels (effect estimate=95.81; 95% CI:39.40, 152.21; 
p<0.01) after controlling for age, gender, smoking, viral load, CD4 cell count and BMI. Heavy use of 
cigarettes  and  crack/cocaine  was  inversely  associated  with  obesity  (OR=0.84,  95%  CI:0.67,  0.99; 
p=0.049; OR=0.43, 95% CI:0.19, 0.98; p=0.044, respectively), while use of marijuana tended to be 
associated  with  increased  central  obesity  (p=0.08).  Heavy  cigarette  smoking  was  significantly 
associated with low HDL (OR=3.06, 95% CI:1.18; 7.95, p=0.02). The significant association of higher 
viral load with CHD risk indicates that controlling viral load may be important in reducing CHD risk 
in HIV infected drug users.  
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INTRODUCTION 
 
  Highly  active  antiretroviral  therapy  (HAART) 
improves the clinical course, prognosis and survival of 
HIV  infected  patients.  Its  prolonged  use,  particularly 
with the protease inhibitors, has been associated with an 
increase in coronary heart disease (CHD) risk
[1-3] and 
with a number of metabolic abnormalities  collectively 
named  metabolic  syndrome
[4-6].  Metabolic  syndrome 
occurs in approximately one quarter of the US general 
population
[7] and in approximately one third of the HIV 
infected patients
[8-10]. With the diagnosis of metabolic 
syndrome, the risk of developing CHD increases three-
fold and the risk of dying from a heart attack or stroke 
doubles
[11].  
  Estimate  of  10-year  coronary  heart  disease  risk 
uses  an  algorithm  that  includes  age,  gender,  blood 
pressure,
  total  cholesterol  and  LDL  cholesterol,  high 
fasting glucose and smoking status
[12]. While a number 
of  studies  have  been  published  to  demonstrate 
metabolic  abnormalities  and  CHD  risk  in  HIV 
seropositive  cohorts
[11,13-17],  to  our  knowledge  no 
reports focus on cohorts of HIV infected drug users and 
the contribution of illicit drugs to CHD risk. Moreover, Am. J. Infectious Dis. 2 (3): 173-179, 2006 
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the  factors  used  to  estimate  CHD  risk  in  the  drug 
abusing  population  may  not  be  accurate  as  the  drug 
abuse  itself  significantly  increases  the  risk
[18].  In  this 
study we have calculated the 10-year CHD risk estimate 
and the prevalence of metabolic syndrome in a cohort 
of HIV seropositive chronic drug users, including those 
who are on HAART with or without protease inhibitors. 
   
MATERIALS AND METHODS 
 
Study design: A cross-sectional study was carried out 
on a cohort of 118 HIV infected drug users recruited 
between  March,  2002  and  December,  2003  from  the 
Camillus House, a non-profit organization that provides 
services  to  the  poor  in  Miami,  Florida.  The  study 
protocol  was  approved  by  the  Florida  International 
University  Internal  Review  Board  and  consisted  of  a 
physical examination including a medical history and 
laboratory  analyses  after  a  12-hour  fast.  Documented 
HIV seropositive status, age 18 to 55 years or older and 
active drug use (determined by urine toxicology) were 
inclusion  criteria  for  the  study.  Sociodemographic, 
alcohol  and  drug  abuse  data  were  collected.  All 
participants  gave  written  informed  consent  prior  to 
enrollment in the study. 
 
Participant  examination  protocol:  Physical 
examination and medical history were performed by a 
nurse practitioner after determination of eligibility. The 
data  collection  tools  emphasized  the  history  of 
infectious  illness,  diabetes,  coronary  artery  vascular 
disease  and  hypertension.  Drug  history  included 
currently prescribed medications, as well as frequency 
and quantity of cigarette smoking, alcohol consumption 
and illicit drug use in the previous 6 months. Height, 
weight  and  waist  circumference  were  obtained  using 
standard methods and blood pressure was measured in 
the  left  arm  with  the  elbow  flexed  to  heart  level. 
Venous blood was drawn for CD4 cell count, viral load, 
blood chemistry and lipid panel; urine was collected for 
toxicology. 
 
Biochemical  assays:  Lymphocyte  phenotype  was 
determined with four-color immunophenotyping panel 
of  monoclonal  antibodies.  Differential  counts  were 
determined  using  a  Coulter  MaxM  hematology 
instrument  and  corroborated  with  cytocentrifuge 
smears.  Viral  load  was  obtained  by  the  reverse 
transcriptase  polymerase  reaction  using  the  Roche 
Amplicor  reagents  and  protocol.  Triglycerides,  total 
cholesterol  and  HDL  were  determined  directly  using 
the  Aeroset 
TM  System  (Abbott  Laboratories),  with 
calculation  of  LDL  and  VLDL  levels.  C-reactive 
protein  was  determined  using  the  CRP  Ultra  Range 
Reagent  Kit  (Equal  Diagnostics),  a  latex-enhanced 
turbidimetric immunoassay. 
Definition  of  10-year  cardiovascular  risk  and 
metabolic  syndrome:  The  10-year  CHD  risk  was 
determined  using  the  algorithm  derived  from  the 
Framingham study to estimate cardiovascular risk in the 
general population
[12]. The risk factors included in the 
Framingham  calculation  of  10-year  risk  are:  age, 
gender,  total  cholesterol,  HDL  cholesterol,  systolic 
blood  pressure,  treatment  for  hypertension,  elevated 
fasting glucose and cigarette smoking. 
  Metabolic syndrome was defined according to the 
guidelines  of  the  National  Cholesterol  Education 
Program  (NCEP)  Adult  Treatment  panel  ATP  III
[4]. 
Participants having ³ 3 of the following factors were 
defined  as  having  metabolic  syndrome:  waist 
circumference > 102 cm in men and 88 cm in women, 
serum  triglycerides  ³  150  mg/dL,  high  density 
lipoprotein (HDL) cholesterol £ 40 mg/dL in men and 
£50 mg/dL in women; blood pressure ³ 130/85 mmHg; 
and serum glucose ³ 110 mg/dL. 
 
Statistical analysis: This is a crossectional study that 
explores the associations of HIV disease, antiretroviral 
treatment and drugs of abuse and CHD risk in a cohort 
of HIV seropositive drug users in Miami. Our analyses 
first focused on the calculation of the 10-year CHD risk 
for the total cohort and by gender using the 10-year risk 
%  derived  from  the  Framingham  multiple-risk-factor 
equation
[12] and the NCEP Adult Treatment panel ATP 
III  guidelines  to  diagnose  metabolic  syndrome
[4].  We 
compared  the  rate  of  10-year  CHD  risk  and  the 
parameters of disease progression, frequency of drug of 
abuse, treatment and characteristics of the participants 
diagnosed  with  metabolic  syndrome  to  those  of 
participants without the syndrome. The association of 
parameters  of  HIV  disease  (viral  load  and  CD4  cell 
count),  antiretroviral  treatment  (HAART  with  and 
without  PIs)  and  drugs  of  abuse  (alcohol,  tobacco, 
cocaine and marijuana) with CHD risks were examined 
using univariate analyses. The significant factors were 
subsequently  included  in  complex  regression  models 
adjusting for other significant variables. 
  Descriptive statistics were used to characterize the 
population.  Student’s  t-test  was  used  to  evaluate  the 
mean  differences  and  ￿
2  tests  were  used  to  evaluate 
percentage differences. Wilcoxon rank sum tests were 
used  when  data  were  not  normally  distributed. 
Univariate  analyses  were  used  to  assess  association 
between  CHD  risk  factors  and  parameters  of  HIV 
disease status, antiretroviral treatment and the type and 
frequency  of  substances  abused.  Logistic  regressions 
and  MANOVA  were  performed  for  multivariate 
analyses. 
 
RESULTS 
 
Characteristics of the population: The cohort of 118 
HIV  seropositive  drug  users  consisted  of  74%  males 
and 83.2% were Black. The mean age of the cohort was 
41.69±6.85 SD. Their mean income was US $393±83 
SD and the mean years of education for the cohort were 
11.36±2.66  SD.  Of  the  total  cohort,  71%  were  on Am. J. Infectious Dis. 2 (3): 173-179, 2006 
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HAART and 36.5% were receiving protease inhibitors. 
The  mean  CD4  count  was  333±262  cells/mm
3  SD 
(316±238  cells/mm
3  SD  for  men  and  382±320 
cells/mm
3 SD for women), mean viral load was 9.3 ± 
2.4 log SD (9.2 ±2.5 log SD for men, 9.6 ± 2.2 log SD 
for women) and the mean C-reactive protein (CRP) was 
4.8 ± 7.8 mg/L SD (7.9 ± 12.8 mg/L SD for men, 4.4 ± 
6.9 mg/L SD for women). Daily alcohol consumption 
was  reported  by  57.6%  of  the  cohort,  while  83.9% 
smoked  cigarettes,  38.1%  used  marijuana  and  67.8% 
used  cocaine/crack.  There  were  no  significant 
differences  between  the  genders  in  any  of  these 
characteristics, although women showed a marked trend 
(p=0.08) towards using more marijuana than men. 
 
Risk  factors  for  coronary  heart  disease  and 
metabolic syndrome: As Table 1 shows, the 10-year 
CHD risk in this cohort of HIV seropositive drug users 
was  4.8±5.7;  the  women  had  significantly  lower  10-
year CHD risk (1.7±2.4, p<0.001) than men (5.9±6.1). 
The prevalence of the metabolic syndrome, on the other 
hand  was  significantly  higher  in  women  (29%, 
p=0.013)  compared  to  men  (10.3  %).  The  factors 
influencing  this  higher  prevalence  of  metabolic 
syndrome  among  women  included  a  significantly 
higher rate of abdominal obesity (54.8% in women vs. 
8.1%  in  men,  p<0.001)  and  lower  HDL  (61.3%in 
women vs. 40% in men, p=0.042).  
  Table  2  shows  that  participants  with  metabolic 
syndrome had a significantly higher estimate of 10-year 
CHD  risk  of  >10%  (27.8%,  p=0.041)  than  those 
without metabolic syndrome (10.2%). The risk factors 
significantly  associated  with  the  metabolic  syndrome 
were  male  gender  (OR=0.28,  95%  CI:  0.10,  0.80; 
p=0.017), Body Mass Index (OR=1.19, 95% CI:1.07, 
1.32; p=0.001), which was significantly higher in those 
with  metabolic  syndrome  (28.6±4.1,  p<0.001) 
compared to those without the syndrome(24.2±4) and 
viral load (OR=1.61, 95% CI:1.02,2.54; p=0.042). The 
paradox of the women having lower CHD risk while 
having  higher  prevalence  of  the  metabolic  syndrome 
appears to arise from the separate algorithm used for 
calculating the 10-year CHD risk for women that also 
takes  into  consideration  their  pre-menopausal  age, 
resulting  in  a  lower  estimate  of  the  CHD  risk  for 
women than men. On the other hand, the definition of 
metabolic syndrome does not take gender and age into 
consideration, causing the apparent contradiction in this 
cohort of the women having lower 10-year CHD risk 
while  having  a  higher  prevalence  of  metabolic 
syndrome  than  men.  The  analyses,  however,  indicate 
that those with metabolic syndrome have a significantly 
higher 10-year CHD risk. 
 
HIV disease progression, antiretroviral medication, 
drugs  of  abuse  and  CHD  risk:  Univariate  analyses 
were  performed  to  identify  significant  associations 
between  HIV  disease  status,  HIV  treatment  regimens 
and  the  types  and  frequency  of  drugs  of  abuse.  As 
shown  in  Table  3,  these  analyses  show  a  significant 
association  between  the  increasing  viral  load  and  the 
risk  of  metabolic  syndrome  (OR=1.61;  95%  CI:1.02, 
2.54;  p=0.042),  high  fasting  glucose  (OR=1.28;  95% 
CI:1.03,1.58; p=0.023) and low HDL (OR=1.37; 95% 
CI:1.03, 1.81; p=0.03). Viral load was also found to be 
inversely correlated with serum cholesterol levels (r=-
0.21, p=0.023) (not shown in the table). There did not 
appear  to  be  a  significant  relationship  between 
increased levels of viral load and plasma triglycerides, 
or blood pressure.  
  Other factors that contributed significantly to CHD 
risk were age, which was associated with high blood 
pressure (OR = 1.1; 95% CI:1.01, 1.19; p = 0.024), high 
serum  triglyceride  (OR  =  1.07;  95%  CI:  1.01,  1.14; 
p=0.024) and cholesterol (OR = 1.09; 95% CI: 1.01, 
1.18; p = 0.019). Obesity, defined as BMI>27 kg/m
3, 
was  associated  with  metabolic  syndrome  (OR=1.19; 
95% CI: 1.07, 1.32; p=0.001), high serum cholesterol 
(OR=1.09;  95%  CI:1.00,  1.20;  p  =  0.05)  and  central 
obesity (OR=1.88; 95% CI:1.46, 2.42; p=0.001). Male 
gender was significantly associated with low levels of 
HDL  (OR=0.42;  95%  CI:0.18,  0.98  ;  p=0.044), 
metabolic  syndrome  (OR=0.28;  95%  CI:0.10,  0.80; 
p=0.017 ), and central obesity (OR=0.07; 95% CI:0.03, 
0.21; p=<0.001). HAART with or without PI did not 
contribute to either the 10-year CHD risk or metabolic 
syndrome  in  this  cohort,  and  CD4  count  was  not 
significantly  related  to  any  of  the  variables  analyzed 
(not shown in tables). 
  C-reactive  protein  (CRP),  an  independent  CHD 
risk  factor  and  a  marker  of  inflammation,  was 
significantly higher in participants  with low levels of 
HDL (7.6±10.6 SD, p=0.008) than in those who did not 
have  overly  low  levels  of  HDL  (2.4±2.5  SD).  In 
multivariate analysis, abnormal CRP (>3 mg L￿
1) was 
significantly associated with low HDL (OR=1.18; 95% 
CI:1.04,1.35;  p=0.012)  and  this  association  remain 
significant after controlling for gender, age, CD4 count, 
viral  load,  obesity,  HAART  and  the  use  of  protease 
inhibitors (not shown in tables).  
  Analysis of the relationship between drugs of abuse 
and CHD risk factors indicate that participants who are 
heavy cocaine/crack users are significantly less likely to 
be on HAART (35.3%, p=0.015) than those  who are 
not heavy drug users (15.5%). Regarding the univariate 
association of drug abuse with CHD risk factors, heavy 
cigarette  use  was  significantly  associated  with  low 
HDL (OR=3.06; CI:1.18, 7.95; p=0.02). Heavy use of 
cigarettes  and  crack/cocaine  was  inversely  associated 
with obesity defined ad BMI of >27 kg/mm
3 (OR=0.84, 
95% CI: 0.67, 0.99; p=0.049; OR=0.43, 95% CI: 0.19, 
0.98;  p=0.044,  respectively),  while  use  of  marijuana 
tended to be associated with central obesity (OR=2.25; 
CI: 0.96, 1.67; p=0.08). Am. J. Infectious Dis. 2 (3): 173-179, 2006 
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Table 1:  Prevalence of CHD risk factors for men and women in a cohort of HIV-seropositive drug users in Miami 
CHD Risk Factors  Total n=118  Men n=87  Women n=31   p-value 
10-year risk %  Mean ± SD   4.8 ± 5.7%   5.9±6.1%   1.7 ± 2.4%   <0.001 
10-year risk   >10%   12.9%   16.5%   3.2%   0.06 
Metabolic Syndrome( >3 risk factors are met)   15.1%   10.3%   29.0%   0.013 
Abdominal obesity 
 (Waist >102 cm in men and >88 cm in women)   20.5%   8.1%   54.8%   <0.001 
High serum triglycerides ( >150 mg/dL)   34.5%   34.1%   35.5%   n.s. 
Low HDL   (£40mg/dL in men and £50 mg/dL in women)   45.7%   40.0%   61.3%   0.042 
High blood pressure  ( >130/85mmHg)   15.3%   14.9%   16.1%   n.s. 
High Systolic blood pressure ( >130mmHg)   11.9%   11.5%   12.9%   n.s. 
High serum glucose  ( Fasting blood glucose of >110 mg/dL)   18.6%   18.4%   19.4%   n.s. 
High total serum cholesterol  ( >200 mg/dL)   19.8%   21.2%   16.1%   n.s. 
 
Table 2:  CHD risk and HIV status in HIV-seropositive drug users with and without metabolic syndrome 
Variables  With metabolic syndrome  Without metabolic syndrome    p- value 
  Mean ± SD  Mean ± SD   
10-year risk  %  8.0 ± 10.2 %  4.2 ± 4.2 %  n.s. 
10-year risk  > 10%   27.8%  10.2%  0.041 
Body Mass Index (kg/m
3)  28.6 ± 4.1  24.2 ± 4.0  <0.001 
CD4 cell count (cells/mm
3)  264 ± 223  346 ± 268  n.s. 
Viral load (log10 copies/ml)  10.3 ± 2.0  9.2 ± 2.4  0.07 
 
Table 3:  Univariate and multivariate analyses of CHD risks significantly associated with viral load  
Univariate Analyses on Viral load (log10 copies/ml)   Odds Ratios   95% CI   p-value 
With metabolic syndrome  ( >3 risk factors are met)   1.61   1.02, 2.54   0.042 
With  high glucose  (Fasting blood glucose of >110 mg/dL)   1.28   1.03, 1.58   0.023 
With low HDL  (£40mg/dL in men and £50 mg/dL in women)   1.37   1.03, 1.81   0.03 
Multivariate Analyses on Viral load (log10 copies/ml)   
With metabolic syndrome* ( >3 risk factors are met)   2.23   1.12, 4.47   0.023 
With high glucose* (Fasting blood glucose of >110 mg/dL)   1.61   1.02, 2.55   0.042 
With low HDL** (£40mg/dL in men and £50 mg/dL in women)   1.41   1.01, 1.98   0.046 
*Models controlled for age, gender, smoking, protease inhibitors, BMI, and CD4 cell count 
** Models controlled for age, gender, smoking, BMI, and CD4 cell count 
 
  As shown in Table 3, the effect of viral load on 
CHD  risk  factors  was  also  examined  in  multivariate 
models.  In  a  multivariate  regression,  increased  viral 
load  remained  associated  with  metabolic  syndrome 
(OR=2.23,  95%  CI:1.12,  4.47;  p=0.023)  after 
controlling for gender, age, smoking, PI exposure, BMI 
and  CD4.  In  addition,  increasing  viral  load  was 
associated with higher blood glucose levels (OR=1.61, 
95%  CI:  1.02,  2.55;  p=0.042)  and  lower  HDL 
(OR=1.41;  95%  CI:1.01,  1.98;  p=0.046)  after 
controlling  for  gender,  age,  smoking,  BMI  and  CD4 
cell count. 
  Higher  BMI  was  the  only  factor  that  remained 
significantly associated  with  higher serum cholesterol 
levels  (p=0.040)  in  a  regression  model  that  included 
viral  load,  age,  gender,  smoking,  CD4  cell  count,  PI 
use, marijuana and cocaine/crack use.  
  The  estimated  effect  of  protease  inhibitors  was 
determined  with  sequential  MANOVA  models  that 
included  age,  gender,  smoking,  viral  load,  CD4  cell 
count and BMI. After controlling  for these variables, 
use of PI was still significantly related to high levels of 
triglyceride  (estimated  effect  =  95.81;  95%  CI:39.40, 
152.21; p<0.01).  
DISCUSSION 
 
  The  results  of  this  study  demonstrate  that  the 
prevalence of metabolic abnormalities and CHD risk in 
our cohort of HIV infected chronic drug users is in the 
range  of  results  published  for  other  HIV  infected 
cohorts. The risk of CHD, however, was considerably 
higher  in  participants  with  metabolic  syndrome.  Our 
cohort of drug abusers had a relatively high mean viral 
load. Increasing viral load was significantly associated 
with metabolic syndrome, high fasting glucose and low 
HDL  levels.  Other  factors  contributing  to  CHD  risk 
were age, male gender, the use of protease inhibitors 
and obesity. Of the drugs of abuse heavy cigarette use 
was associated with low HDL levels. Marijuana use on 
the other hand, was associated with obesity, although 
not  significantly,  while  cigarette  smoking  and 
crack/cocaine  use  were  inversely  and  significantly 
associated with obesity. 
  The  10-year  CHD  risk  was  calculated  using  the 
algorithms  developed  in  the  Framingham  study  to 
estimate cardiovascular disease risk and validated in the 
general  population.  The  score  takes  into  account  the 
following  parameters:  age,  gender,  total  cholesterol, 
HDL-cholesterol,  systolic  blood  pressure,  elevated 
fasting  glucose  and  smoking
[12].  The  score  has  been 
shown to accurately predict myocardial infarction rates 
in  the  Framingham  Study
[12]  and  in  HIV  infected 
individuals receiving HAART
[19]. CHD risk studies in 
HIV  infection  showed  that  while  age,  gender  and 
smoking were the primary risk factors, adverse effects 
of  HAART  added  metabolic  complications  and  a 
substantial risk
[19,20].  Am. J. Infectious Dis. 2 (3): 173-179, 2006 
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  The prevalence of a 10-year CHD risk in the HIV 
seropositive population of chronic drug users in Miami 
(4.8%  ±  5.7)  was  similar  to  the  4.1-7.6%  previously 
reported  for  an  HIV  infected  cohort  and  5.3%  in  a 
matched control group of HIV seronegative  men and 
women  from  the  Framingham  data
[21].  The  10-year 
CHD risk for our HIV infected cohort of drug users was 
also  similar  to  the  overall  rate  (5%)  reported  for  a 
homeless  drug-using  HIV  seronegative  cohort  in 
Toronto
[22].  The  CHD  risk  was  significantly  lower 
among the HIV infected women drug users (1.7% ± 2.4 
SD  in  women  vs.  5.9%  ±  6.1  SD  in  men,  p=0.001), 
which appears to be mainly due to their gender and to 
the pre-menopausal mean age of the women of 39.4 ± 
7.3 SD years
[23]. 
  Despite  the  lower  CHD  risk,  the  prevalence  of 
metabolic syndrome was significantly higher among the 
women (29% vs. 10.3% among  men, p=0.013), most 
likely due to the high rates of abdominal obesity, higher 
BMI  and  higher  rates  of  low  HDL  levels  among 
women. These results are in agreement  with a report 
from another urban HIV positive cohort, which shows 
similar rates of obesity among HIV infected women
[24]. 
The  overall  prevalence  of  15.1%  of  metabolic 
syndrome in our cohort, however, was lower than the 
estimated  22%  prevalence  in  the  US  general 
population
[7]  and  the  33.1%  prevalence  of  metabolic 
syndrome estimated by Bruno and colleagues
[9] in HIV 
infected patients on HAART.  
  Participants  with  metabolic  syndrome  had  a 
significantly  higher  estimate  of  10-year  CHD  risk  of 
³10% (27.8%, p=0.041) than those without metabolic 
syndrome  (10.2%).  This  is  in  agreement  with  earlier 
findings  that  show  that  metabolic  syndrome  is  an 
independent  cardiovascular  risk  factor,  with  a 
significant  3-fold  increase  in  risk  for  coronary  heart 
disease  and  stroke  and  a  markedly  increased 
cardiovascular  mortality  in  both  men  and  women.  In 
addition,  Isomaa  and  colleagues
[11]  also  demonstrated 
that cardiovascular morbidity and mortality associated 
with this cluster of risk factors was greater than those 
related to each component alone. The risk factors that 
significantly influenced the metabolic syndrome in our 
cohort  were  female  gender,  central  obesity  and  low 
HDL levels. The apparent paradox in our findings of 
the  low  10-year  CHD  risk  in  women,  while  it  was 
predominantly  the  women  who  had  the  metabolic 
syndrome and consequently, higher percent of 10-year 
CHD  risk,  reflects  on  one  hand  the  lower  risk  in 
females because of their gender and age using the 10-
year  CHD  risk  algorithm,  while  the  estimation  of 
metabolic syndrome does not take age and gender into 
consideration. The analyses indicated however, that the 
29%  of  the  women  in  our  cohort  with  metabolic 
syndrome have an increased CHD risk. 
  A primary finding in this study is the observation 
that increasing viral load  was significantly associated 
with metabolic syndrome, high fasting glucose and low 
HDL levels and that viral load was inversely associated 
with  total  cholesterol  in  our  cohort  of  HIV  infected 
drug  users.  Our  findings  are  consistent  with  recently 
reported  data  in  HIV  infected  women  showing  a 
significant inverse association between viral load and 
serum  cholesterol  levels
[24]  and  with  results  from 
another  study
[25]  that  showed  an  association  between 
higher HIV RNA levels and lower HDL cholesterol in 
antiretroviral-naïve  HIV  infected  inner  city  men  and 
women and suggested that high viral replication has a 
direct  effect  on  serum  lipid  levels.  In  addition,  other 
investigators
[14,26] have proposed a possible etiological 
link  between  inflammation  caused  by  viruses  and 
endothelial  dysfunction,  which  may  increase 
cardiovascular  risk  by  eventually  producing  clinical 
atherosclerosis.  Our  findings  also  contribute  to  this 
hypothesis,  as  CRP,  an  independent  predictor  of 
CHD
[27]and  a  marker  of  inflammation
[28],  was 
significantly higher in participants with low HDL when 
compared to those with adequate HDL. Abnormal CRP 
was also significantly associated with low HDL in our 
cohort.  Elevated  levels  of  CRP  were  not  related  to 
obesity,  metabolic  syndrome  or  other  variables 
measured,  in  contrast  to  findings  from  a  previous 
study
[24].  Increased  viral  load  in  our  cohort  was 
associated  with  elevated  levels  of  fasting  glucose, 
which is likely to contribute to the 10-year CHD risk 
via the metabolic syndrome
[29]. 
  The  findings  from  our  cohort  indicate  that  a 
predominant  portion  of  these  HIV  infected  drug 
abusing  participants  have  a  high  viral  load  and  that 
increasing  viral  load  was  associated  with  metabolic 
syndrome,  high  fasting  glucose  and  low  HDL  levels. 
The  high  mean  viral  load  found  in  our  cohort  is 
consistent with previous reports suggesting that heavy 
use of illicit drugs has an influence on either adherence 
or  effectiveness  of  antiretroviral  medication  and 
therefore,  on  viral  control  in  intravenous  drug 
users
[30,31].  
  In  our  cohort,  participants  who  are  heavy 
cocaine/crack users are significantly less likely to be on 
HAART  (35.3%,  p=0.015)  than  those  who  are  not 
heavy drug users (15.5%). Moreover, drugs of abuse, 
particularly the combination of cocaine and ethanol
[18,32] 
were  previously  reported  to  have  an  additive  or 
synergistic  effect
  on  cardiovascular  events. 
Concomitant
  cigarette  smoking  also  has  deleterious 
effects  on  myocardial  oxygen
  supply  and  demand
[33]. 
The  drugs  of  abuse  of  choice  of  our  participants,  in 
order  of  prevalence  were  cigarette  smoking,  cocaine, 
alcohol  and  marijuana.  Heavy  use  of  cigarettes  and 
crack  cocaine  were  significantly  and  inversely 
associated  with  obesity  in  our  cohort,  which  is 
consistent  with  our  previous  report  linking  heavy 
cocaine  use  with  wasting
[34]  and  with  the  anorectic 
effect of these drugs
[35-37]. Marijuana use on the other Am. J. Infectious Dis. 2 (3): 173-179, 2006 
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hand,  a  known  appetite  stimulant,  tended  to  be 
associated with central obesity in our cohort, although 
not significantly. Evaluating the independent effects on 
coronary  risk  of  both  cocaine  and  marijuana  in  this 
cohort has been rather difficult, because the drugs may 
be  used  in  combination  or  singly,  depending  on  the 
availability. In addition, the purity, mode of ingestion 
and degree of absorption of street drugs varies greatly, 
making comparison less meaningful.  
  Other factors contributing to CHD risk were age, 
male gender, the use of protease inhibitors and obesity. 
These findings are consistent with previous studies of 
CHD  risk  factors  in  both  HIV  seronegative  and 
seropositive populations
[19,21,29,38]. The use of protease 
inhibitors  appears  to  be  associated  with 
hypertriglyceridemia  and  an  increased  CHD  risk
[16]. 
The  strong  association  between  the  use  of  protease 
inhibitors  and  elevated  levels  of  triglycerides  in  our 
cohort is consistent with the previous findings and has 
an effect on the CHD risk  via its contribution to the 
prevalence of metabolic syndrome. Obesity, through its 
association with central obesity, is also a contributing 
factor to metabolic syndrome and consequently to CHD 
risk, in our cohort
[39]. 
  Overall, the findings from our cohort indicate that a 
predominant  portion  of  these  HIV  infected  drug 
abusing participants have a high viral load, suggesting 
that heavy use of illicit drugs has an influence on either 
adherence or effectiveness of antiretroviral medication 
and therefore, on viral control. Increasing viral load was 
associated  with  metabolic  syndrome,  high  fasting 
glucose  and  low  HDL  levels.  The  prevalence  of 
metabolic abnormalities and CHD risk is in the range of 
results published for other HIV infected cohorts. The 
10-year CHD risk was, however, considerably higher in 
participants  with  metabolic  syndrome.  Other  factors 
contributing  to  CHD  risk  were  age,  male  gender, 
abnormal  levels  of  C-reactive  protein,  the  use  of 
protease inhibitors and obesity. Of the drugs of abuse 
heavy  cigarette  use  was  associated  with  low  HDL 
levels. Marijuana use on the other hand, was associated 
with obesity, although not significantly, while cigarette 
smoking  and  cocaine  use  were  inversely  and 
significantly  associated  with  obesity.  Interventions  to 
improve control of viral load and obesity are needed to 
lower the risks for CHD in this population exposed to 
chronic HIV-infection, HAART and drug abuse.  
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